Dysregulation of METTL3 expression has been associated with various cancers and pharmacological modulation of RNA methylation using small molecule modulators (inhibitors and/or activators) has great therapeutic potential for supporting cancer therapy.[27] Therefore, we studied the efficacy of a previously reported METTL3‐14‐WTAP activator (Figure 9A)[28] in the treatment of thyroid cancer, thus providing an innovative approach for the redifferentiation treatment of thyroid cancer. This evidence concerns the gene WTAP and thyroid gland carcinoma.